BG
BGLC.US BioNexus Gene Lab Corp Common stock
- Market cap
- USD 2.41M
- P/E
- -
- P/B
- 0.34x
- ROE
- -21.3%
- Dividend yield
- 0.92%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is BGLC.US undervalued?
Graham numberThe Graham number of BioNexus Gene Lab Corp Common stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BioNexus Gene Lab Corp Common stock fundamental analysis
No fundamental analysis for BioNexus Gene Lab Corp Common stock yet.
BioNexus Gene Lab Corp Common stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp., together with its subsidiaries, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; and Investment Holding. It offers various chemical raw material products, i…
Full company profileBioNexus Gene Lab Corp Common stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BioNexus Gene Lab Corp Common stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | 108K | 212K | 127K | 11.4M | 13.4M | 10.9M | 9.77M | 9.51M | 7.42M | 198K |
| Gross Profit | - | 78.8K | 28.8K | 55.9K | 1.72M | 2.19M | 1.26M | 1.33M | 1.29M | 1.09M | -19.5K |
| Operating Income | -840.00 | -128K | 59.9K | -276K | 1.27M | 1.06M | -291K | -2.59M | -1.57M | -3.16M | -1.71M |
| EBITDA | - | -104K | 101K | -222K | 1.38M | 1.16M | -186K | -2.49M | -1.42M | -2.80M | -1.47M |
| Net Income | -835.00 | -124K | 26.5K | -246K | 1.09M | 752K | -356K | -2.63M | -1.60M | -2.98M | -1.66M |
| EPS | 0.00 | -0.20 | 0.05 | -0.34 | 1.28 | 0.53 | -0.25 | -1.53 | -0.90 | -1.61 | -0.69 |
| Balance Sheet | |||||||||||
| Total Assets | 26.00 | 1.27M | 1.65M | 1.23M | 10.1M | 9.57M | 8.74M | 11.4M | 10.4M | 9.25M | 8.73M |
| Total Liabilities | 1.34K | 1.18M | 130K | 109K | 3.45M | 2.39M | 2.08M | 1.74M | 2.11M | 638K | 948K |
| Shareholders' Equity | -1.31K | 94.6K | 1.52M | 1.12M | 6.66M | 7.18M | 6.67M | 9.66M | 8.32M | 8.61M | 7.78M |
| Cash & Short-term Investments | 26.00 | 839K | 1.26M | 859K | 2.79M | 2.12M | 2.12M | 5.93M | 4.38M | 2.38M | 3.52M |
| Total Debt | - | - | 82.1K | 89.4K | 123K | 76.9K | 56.8K | 147K | 211K | 176K | 199K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -835.00 | 357K | -274K | -217K | 553K | 9.16K | 544K | -1.76M | -2.23M | -1.84M | -1.14M |
| Capital Expenditure | 0.00 | 315K | 39.6K | 12.8K | 422K | 3.16K | 54.2K | 149K | 227K | 37.0K | 43.2K |
| Free Cash Flow | -835.00 | 42.4K | -314K | -230K | 131K | 6.00K | 490K | -1.91M | -2.46M | -1.88M | -1.18M |
| Ratios | |||||||||||
| ROE | - | -130.8% | 1.7% | -22.0% | 16.4% | 10.5% | -5.3% | -27.2% | -19.2% | -34.6% | -21.3% |
| ROA | -3,211.5% | -9.7% | 1.6% | -20.0% | 10.8% | 7.8% | -4.1% | -23.1% | -15.3% | -32.3% | -19.0% |
| Net Profit Margin | - | -114.9% | 12.5% | -194.1% | 9.6% | 5.6% | -3.3% | -26.9% | -16.8% | -40.2% | -838.4% |
| Debt to Equity | - | - | 0.05x | 0.08x | 0.02x | 0.01x | 0.01x | 0.02x | 0.03x | 0.02x | 0.03x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
BioNexus Gene Lab Corp Common stock dividends
- Dividend yield
- 0.92%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 22.1K | 0.01 | - |
| 2024 | USD 68.1K | 0.04 | - |
| 2023 | USD 115K | 0.07 | - |
| 2022 | USD 0.12 | 0.00 | - |
| 2021 | USD 22.0K | 0.02 | 2.9% |
| 2020 | USD 6.31K | 0.01 | 0.6% |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:10 on Apr 7, 2025.
Who owns BioNexus Gene Lab Corp Common stock
- Insiders 44.72%
- Institutions 0.50%
- Public & others 54.78%
- Shares outstanding 2.93M
- Free float 1.67M
Top funds holding BGLC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Nasdaq Composite Index | 2.37K | 0.10% | 0.00% | May 2026 |
Top institutions holding BGLC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| HRT FINANCIAL LLC | 14.3K | 0.49% | 0.00% | Jun 2026 |
| UBS Group AG | 101.00 | 0.00% | -56.28% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 1.00 | 0.00% | 0.00% | Jun 2026 |
| Wells Fargo & Co | 0.00 | 0.00% | -100.00% | Jun 2026 |
BioNexus Gene Lab Corp Common stock company profile
- Company name
- BioNexus Gene Lab Corp Common stock
- Ticker
- BGLC.US
- Exchange
- USA Stocks
- Listed since
- Sep 16, 2020
- Sector
- Basic Materials
- Industry
- Chemicals
- Employees
- 19
- Fiscal year end
- December
- Address
- Menara UOA Bangsar, Kuala Lumpur, Malaysia, 59000
- Phone
- 60 1 307 241 6898
- Website
- bionexusgenelab.com
About BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp., together with its subsidiaries, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; and Investment Holding. It offers various chemical raw material products, including polyester resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; polyester resin 9509, a general-purpose material used in the production of marine boats and water slides; and polyester resin 2802, which is used as a component in the pultrusion process. The company's products are used in producing various finished goods, such as handrails, bench tops, and automotive and aero parts; paneling for hospital, laboratory, and industrial clean rooms; and covers for various instruments used in manufacturing. It develops and provides non-invasive liquid biopsy tests for the early detection of biomarkers. BioNexus Gene Lab Corp. was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.
BioNexus Gene Lab Corp Common stock management
4- Mr. Su-Leng TanCEO, President, Secretary & Director · born 1983
- Ms. Set Fui ChongChief Financial Officer · born 1963
- Mr. Kwan Wah ChanMarketing Manager
- Mr. Too Kam ThamManaging Director